We are excited to announce that DNASequence Hellas is among the companies that are included in the funding through the EU co-funded program of Research-Create-Innovate.
The funding regards the program: Monitoring and Tracing of authentic materials, allergenics and pathogens, in high value nutritional products with new methods of metagenomic analysis.
This is another stepping stone strengthening our efforts towards achieving technical and commercial excellence, as well as establishing DNASequence Hellas as one of the pioneering biotechnology companies in Europe and beyond.
As a company, we are dedicated to excellence and maximum return of our scientific capital, and the same holds for maximizing the return of this welcomed financial boost.